Epileptic Disorders
MENUEpidiolex-induced skin rash Volume 22, numéro 4, August 2020
Auteurs
The Ohio State University Wexner Medical Center, Neurology department, Columbus, Ohio, USA
* Correspondence: Jaysingh Singh
The Ohio State University Wexner Medical Center,
Neurology department,
Columbus, Ohio, USA
- Mots-clés : Epidiolex, cannabinoid, skin, rash, hypersensitivity reaction, antiepileptics, drug interaction, CBD, Epidiolex® (cannabidiol)
- DOI : 10.1684/epd.2020.1189
- Page(s) : 511-4
- Année de parution : 2020
Epidiolex® (cannabidiol, aka CBD) is a recently approved FDA prescription drug for the treatment of epilepsy associated with Lennox-Gastaut and Dravet syndromes, and is increasingly used for treatment-resistant epilepsy. Rash was rarely reported in Epidiolex® clinical trial data. We report a case of Epidiolex®-related skin rash that developed in a delayed fashion in a 23-year-old female with medically refractory epilepsy. We also review the potential mechanism of Epidiolex®-related skin rash.